Article ID Journal Published Year Pages File Type
8647576 Multiple Sclerosis and Related Disorders 2018 5 Pages PDF
Abstract

- IL-6 may represent one of the major treatment target molecules for NMOsd.
- IL-6 upregulates VEGF synthesis causing lymphangiogenesis.
- Tocilizumab may represent first-line medication for NMO with cancer.
Related Topics
Life Sciences Biochemistry, Genetics and Molecular Biology Genetics
Preview
Treatment for paraneoplastic neuromyelitis optica spectrum disorder (NMOsd): Probable effects of tocilizumab for both cancer and NMOsd
Authors
, , ,